News Releases
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Feb 24, 2022- Initiated Enrollment in Phase 3 ENSURE Program of Vidofludimus Calcium for the Treatment of Relapsing Multiple Sclerosis; Final Cohort 2 Data from the Phase 2 EMPhASIS Trial Confirms Phase 3 Dose Selection -
-
Feb 18, 2022Top-Line Data of the CALDOSE-1 Trial Expected to be Available in June of 2022
-
Feb 17, 2022- Webcast to be Held at 8:00 am ET on February 24, 2022 -
-
Dec 14, 2021- Unblinded Data Established a Favorable Safety and Tolerability Profile for IMU-935 in Single Dose and 14-Day Multiple Dose Assessments in Healthy Human Subjects -
-
Nov 4, 2021- Fully Enrolled Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis -
-
Nov 1, 2021- Webcast to be Held at 8:00 am ET on November 4, 2021 -
-
Oct 28, 2021- Top-Line Data Expected in the Second Quarter of 2022 -
-
Oct 27, 2021- Represents the First Time Patients Will Be Treated With the Company's Potentially Best-In-Class RORγt Inverse Agonist -
-
Sep 28, 2021- Three Abstracts, Including One Late-Breaker, to be Presented on IMU-838, the Company's Selective Oral DHODH Inhibitor, at the 37th Congress of ECTRIMS -
-
Sep 22, 2021- Preclinical Combination Data Suggests Extra-Ordinary Synergy Between Certain DHODH Inhibitors and Nucleoside Analogues -
-
Aug 6, 2021- Received FDA Clearance to Initiate Twin IMU-838 Phase 3 ENSURE Trials in Relapsing-Remitting Multiple Sclerosis and Supportive Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis -
-
Jul 12, 2021- IMU-935 Has Been Observed In Vitro to Inhibit the Generation of Th17 Cells and Production of IL-17 Cytokines Without Impairing RORγt Function Required for Normal Thymocyte Development; May Avoid Risk of Lymphoma Formation Seen in Third-Party RORγt Programs -
-
Jul 1, 2021- Phase 3 ENSURE Program in Relapsing-Remitting Multiple Sclerosis (RRMS) Comprises Twin Studies Evaluating Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo, Intended to Provide Straightforward Path to Regulatory Approval -